WebExosome (Bio-Techne) Feb 2024 - Present4 years 3 months. Waltham, MA. My responsibilities are to provide support for all end user hardware and … Webvalidated antibodies to common exosome targets listed in Table 2. Certain targets, such as the integral membrane protein Flotillin-1, are canonical exosome markers and ubiquitously expressed in most exosomes. As expected, Flotillin-1 was found in all exosome standards we tested (Figure 1A). Conversely, some proteins are specific to the
BIO-TECHNE TO SHOWCASE INNOVATIVE CANCER …
WebThe deal with Thermo Fisher is for the development of Bio-Techne's second test in its Exosome Diagnostics portfolio, a multigene assay for kidney transplant rejection. … WebJun 26, 2024 · Bio-Techne has agreed to acquire Exosome Diagnostics for up to $575 million, in a deal intended to position the buyer as a leader in non-invasive liquid biopsies and a developer of diagnostics for chimeric antigen receptor T cell (CAR-T) cancer therapies. Headquartered in Waltham, MA, Exosome Diagnostics is a developer of … subheap
Exosome Diagnostic’s Exosome Platform Bio-Techne
WebMar 8, 2024 · MINNEAPOLIS, March 8, 2024 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has published preliminary data on its kidney transplant rejection test, ExoTRU™ (Exosome Transplant Rejection Urine), a non-invasive multigene urine-based exosomal mRNA … WebJun 26, 2024 · The company purchased Exosome Diagnostics for $250 million. Minneapolis-based biotech supplier Bio-Techne Corp. has agreed to pay $250 million, and maybe more, to acquire a promising Boston-area ... WebApr 13, 2024 · An exosome-based ESR1 monitoring RT-qPCR technology that rapidly and accurately detects circulating tumor acquired resistance variants at ≤0.1% frequency in … subhealth who